Research Article
BibTex RIS Cite

Cytotoxicity Analysis of the Effects of Heterobasidion Annosum Mycelia and Cisplatin on Colon Adenocarcinoma (CACO-2) Cell Line

Year 2024, Volume: 45 Issue: 1, 105 - 110, 28.03.2024

Çiğdem Sevim , Sabri Ünal , Temel Kan Bakır , Mertcan Karadeniz , Ali Taghizadeh Tgzd

https://doi.org/10.17776/csj.1357215

Abstract

Colorectal cancer ranks as the third most prevalent form of cancer and stands as the second leading cause of mortality. Both environmental and genetic risk factors contribute to its manifestation. Presently, 5-fluoruracil/leucovorin (5-FU/LV) remains the recommended course for adjuvant therapy in addressing this condition. Conversely, mushrooms, celebrated for their biologically active constituents, including valuable enzymes, have emerged as a captivating subject in diverse medical disciplines, particularly within the realm of cancer therapy, due to their promising therapeutic properties. This specific investigation aimed to conduct in vitro cytotoxic experiments using extracts obtained from Heterobasidion annosum micelles cultivated in a liquid malt extract medium. The pulverized extracts were dissolved in Dulbecco's Modified Eagle Medium (DMEM) at varied concentrations ranging from 25ng/mL to 200ng/mL and subsequently administered to colon adenocarcinoma (Caco-2) cells. The cytotoxic effects of both the fungus and cisplatin, a well-known anticarcinogenic agent, were examined at intervals of 24, 48, and 72 hours. The findings indicated a significant inhibition of cancer cell development within this timeframe. Moreover, a noteworthy discovery emerged, revealing that cisplatin, known for its efficacy in various cancer studies, substantially diminished the viability of cancer cells after 72 hours in comparison to the control group.

Keywords

Cisplatin Colon adenocarcinoma Heterobasidion annosum

Thanks

We would like to thank Isparta University of Applied Sciences Faculty of Forestry faculty member Dr. Lecturer Ayşe Gülden ADAY KAYA for providing the Heterobasidion annosum isolate TR501 used in the study and contributing to our study.

References

  • [1] Lotfollahzadeh S., Recio-Boiles A., Cagir B., Colon cancer, Florida: StatPearls Treasure, (2021).
  • [2] Alvarez-Gonzalez MA., Pantaleon MA., Flores-Le Roux JA., Zaffalon D., Amorós J., Bessa X., Seoane A., Pedro-Botet J., Randomized Clinical Trial: A Normocaloric Low-Fiber Diet the Day Before Colonoscopy Is the Most Effective Approach to Bowel Preparation in Colorectal Cancer Screening Colonoscopy, Dis Colon Rectum., 62(4) (2019) 491-497.
  • [3] Peters WR., What Every Colorectal Surgeon Should Know About the New American Cancer Society's Colorectal Cancer Screening Guidelines, Dis Colon Rectum., 62(4) (2019) 397-398.
  • [4] Dasari S., Tchounwou PB., Cisplatin in cancer therapy: molecular mechanisms of action, Eur J Pharmacol., 740 (2014) 364-78.
  • [5] Galligioni E., Canobbio L., Figoli F., Fassio T., Frustaci S., Crivellari D., Vaccher E., Lo Re G., Gasparini G., Veronesi A,. Cisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: a phase II study, Eur J Cancer Clin Oncol., 23(6) (1987) 657-61.
  • [6] Gürbüz V., Yilmaz A., Gökçe Ö., Konaç E., İnsan kolon kanser hücre hattında (HT29) sisplatin'in apoptotik etkisi, MarmaraMedJ 24 (2) (2011) 100-105.
  • [7] Kaźmierczak-Siedlecka K., Dvořák A., Folwarski M., Daca A., Przewłócka K., Makarewicz W., Fungal Gut Microbiota Dysbiosis and Its Role in Colorectal, Oral, and Pancreatic Carcinogenesis, Cancers (Basel), 12(5) (2020)1326.
  • [8] Mann, J., Natural products in cancer chemotherapy: past, present and future, Nat Rev Cancer., 2(2) (2002)143-148.
  • [9] Reddy L., Odhav B., Bhoola KD., Natural products for cancer prevention: a global perspective, Pharmacol Ther., 99(1) (2003) 1-13.
  • [10] Sande D, Oliveira GP, Moura MAFE, Martins BA, Lima MTNS, Takahashi JA., Edible mushrooms as a ubiquitous source of essential fatty acids, Food Res Int., 125 (2019)108524.
  • [11] Yilmaz, N., Solmaz, M., Türkekul, I., Elmastaş, M., Fatty acid composition in some wild edible mushrooms growing in the middle Black Sea region of Turkey, Food Chem., 99(1) (2006) 168-174.
  • [12] Feeney MJ, Dwyer J, Hasler-Lewis CM, Milner JA, Noakes M, Rowe S, Wach M, Beelman RB, Caldwell J, Cantorna MT, Castlebury LA, Chang ST, Cheskin LJ, Clemens R, Drescher G, Fulgoni VL 3rd, Haytowitz DB, Hubbard VS, Law D, Myrdal Miller A, Minor B, Percival SS, Riscuta G, Schneeman B, Thornsbury S, Toner CD, Woteki CE, Wu D. Mushrooms and Health Summit proceedings. J Nutr., 144(7) (2014) 1128S-1136S.
  • [13] Simmons EG., The International Mycological Association: its history in brief with summaries of its International Mycological Congresses and diverse international relationships, IMA Fungus., 1(1) (2010) 18-100.
  • [14] Asiegbu FO., Abu S., Stenlid J., Johansson M., Sequence polymorphism and molecular characterization of laccase genes of the conifer pathogen Heterobasidion annosum, Mycol Res., 108(Pt 2) (2004) 136-48.
  • [15] Haars A., Chet, I., Hüttermann A., Effect of phenolic com-pounds and tannin on growth and laccase activity of Fomes annosus, For. Pathol., 11(1–2) (1981) 67–76.
  • [16] Daniel G., Asiegbu F., Johansson M., The saprotrophic wood-degrading abilities of Heterobasidium annosum intersterility groups P and S, Mycol. Res., 102(8) (1998) 991-997.
  • [17] Doğmuş Lehtijarvi H., Lehtijarvi A., Oskay F., Aday A., Karadeniz M., Incidence of Annosum Root and but Rot on Abies Bornmulleriana and Abies Cilicica, ACUJFF., 9 (2008 ) 111-120.
  • [18] Korhonen K., Capretti P., Karjalainen R., Stenlid J., Distribution of Heterobasidion annosum intersterility groups in Europe. In: Heterobasidion annosum: Biology, Ecology, Impact and Control (Woodward S., Stenlid J., Karjalainen R., Hütterman A., eds), CAB International., (1998) 93–105.
  • [19] Garbelotto M., Gonthier P., Biology, epidemiology, and control of Heterobasidion species worldwide, Annu. Rev. Phytopathol., 51(1) (2013) 39-59.
  • [20] Sadowska A., Zapora E., Sawicka D., Niemirowicz-Laskowska K., Surażyński A., Sułkowska-Ziaja K., Kała K., Stocki M., Wołkowycki M., Bakier S., Pawlik A., Jaszek M., Muszyńska B., Car H., Heterobasidion annosum Induces Apoptosis in DLD-1 Cells and Decreases Colon Cancer Growth in In Vivo Model, Int J Mol Sci., 21(10) (2020) 3447.
  • [21] Kladar NV., Gavarić NS., Božin BN., Ganoderma: insights into anticancer effects, Eur J Cancer Prev., 25(5) (2016) 462-71.
  • [22] Glamočlija J., Ćirić A., Nikolić M., Fernandes Â., Barros L., Calhelha RC., Ferreira IC., Soković M., van Griensven LJ., Chemical characterization and biological activity of Chaga (Inonotus obliquus), a medicinal "mushroom", J Ethnopharmacol., 162 (2015) 323-32.
  • [23] Varmazyari A., Taghizadehghalehjoughi A., Sevim C., Baris O., Eser G., Yildirim S., Hacimuftuoglu A., Buha A., Wallace DR., Tsatsakis A., Aschner M., Mezhuev Y., Cadmium sulfide-induced toxicity in the cortex and cerebellum: In vitro and in vivo studies, Toxicol Rep., 7 (2020) 637-648.
  • [24] Bray F., Ferlay J., Soerjomataram I., Siegel RL., Torre LA., Jemal A., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin., 68(6) (2018) 394-424.
  • [25] Sadowska A., Sawicka D., Godlewska K., Guzińska-Ustymowicz K., Zapora E., Sokołowska E., Car H., Beneficial Proapoptotic Effect of Heterobasidion Annosum Extract in Colorectal Cancer Xenograft Mouse Model, Molecules., 28(3) (2023) 1352.
  • [26] Torres DM., Tooley KL., Butler RN., Smith CL., Geier MS., Howarth GS., Lyprinol only partially improves indicators of small intestinal integrity in a rat model of 5-fluorouracil-induced mucositis, Cancer Biol Ther., 7(2) (2008) 295-302.
  • [27] Bunz F., Hwang PM., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler KW., Vogelstein B., Disruption of p53 in human cancer cells alters the responses to therapeutic agents, J Clin Invest., 104(3) (1999) 263-9.
  • [28] Jakopovic, Boris, Nada Oršolić, and Sandra Kraljević Pavelić. "Antitumor, immunomodulatory and antiangiogenic efficacy of medicinal mushroom extract mixtures in advanced colorectal cancer animal model." Molecules 25.21 (2020): 5005.
  • [29] Dalman, K., Olson, A., Stenlid, J., 2010. Evolutionary history of the conifer root rot fungus Heterobasidion annosum sensu lato. Mol. Ecol. 19 (2010): 4979–4993.
  • [30] Linzer, R.E., Otrosina, W.J., Gonthier, P., Bruhn, J., Laflamme, G., Bussieres, G., Garbelotto, M.,. Inferences on the phylogeography of the fungal pathogen Heterobasidion annosum, including evidence of the interspecific horizontal genetic transfer and of human-mediated, long-range dispersal. Mol. Phylogenet. Evol. 46 (2008): 844–862.
  • [31] Hoque, E., Growth inhibitors produced by the in vitro culture of Heterobasidion annosum. Forest Pathol. 14 (1984): 43–51.
  • [32] Hirotani, M., O´ Reilly, J., Donnelly, D.M.X., Fomannoxin – toxic metabolites of Fomes annosus. Tetrahedron Lett. 18 (1977): 651–652.
  • [33] David Hansson, Sileshi Wubshet, Åke Olson, Magnus Karlsson, Dan Staerk, Anders Broberg, Secondary metabolite comparison of the species within the Heterobasidion annosum s.l. complex, Phytochemistry, 108 (2014): 243-251.

Year 2024, Volume: 45 Issue: 1, 105 - 110, 28.03.2024

Çiğdem Sevim , Sabri Ünal , Temel Kan Bakır , Mertcan Karadeniz , Ali Taghizadeh Tgzd

https://doi.org/10.17776/csj.1357215

Abstract

References

  • [1] Lotfollahzadeh S., Recio-Boiles A., Cagir B., Colon cancer, Florida: StatPearls Treasure, (2021).
  • [2] Alvarez-Gonzalez MA., Pantaleon MA., Flores-Le Roux JA., Zaffalon D., Amorós J., Bessa X., Seoane A., Pedro-Botet J., Randomized Clinical Trial: A Normocaloric Low-Fiber Diet the Day Before Colonoscopy Is the Most Effective Approach to Bowel Preparation in Colorectal Cancer Screening Colonoscopy, Dis Colon Rectum., 62(4) (2019) 491-497.
  • [3] Peters WR., What Every Colorectal Surgeon Should Know About the New American Cancer Society's Colorectal Cancer Screening Guidelines, Dis Colon Rectum., 62(4) (2019) 397-398.
  • [4] Dasari S., Tchounwou PB., Cisplatin in cancer therapy: molecular mechanisms of action, Eur J Pharmacol., 740 (2014) 364-78.
  • [5] Galligioni E., Canobbio L., Figoli F., Fassio T., Frustaci S., Crivellari D., Vaccher E., Lo Re G., Gasparini G., Veronesi A,. Cisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: a phase II study, Eur J Cancer Clin Oncol., 23(6) (1987) 657-61.
  • [6] Gürbüz V., Yilmaz A., Gökçe Ö., Konaç E., İnsan kolon kanser hücre hattında (HT29) sisplatin'in apoptotik etkisi, MarmaraMedJ 24 (2) (2011) 100-105.
  • [7] Kaźmierczak-Siedlecka K., Dvořák A., Folwarski M., Daca A., Przewłócka K., Makarewicz W., Fungal Gut Microbiota Dysbiosis and Its Role in Colorectal, Oral, and Pancreatic Carcinogenesis, Cancers (Basel), 12(5) (2020)1326.
  • [8] Mann, J., Natural products in cancer chemotherapy: past, present and future, Nat Rev Cancer., 2(2) (2002)143-148.
  • [9] Reddy L., Odhav B., Bhoola KD., Natural products for cancer prevention: a global perspective, Pharmacol Ther., 99(1) (2003) 1-13.
  • [10] Sande D, Oliveira GP, Moura MAFE, Martins BA, Lima MTNS, Takahashi JA., Edible mushrooms as a ubiquitous source of essential fatty acids, Food Res Int., 125 (2019)108524.
  • [11] Yilmaz, N., Solmaz, M., Türkekul, I., Elmastaş, M., Fatty acid composition in some wild edible mushrooms growing in the middle Black Sea region of Turkey, Food Chem., 99(1) (2006) 168-174.
  • [12] Feeney MJ, Dwyer J, Hasler-Lewis CM, Milner JA, Noakes M, Rowe S, Wach M, Beelman RB, Caldwell J, Cantorna MT, Castlebury LA, Chang ST, Cheskin LJ, Clemens R, Drescher G, Fulgoni VL 3rd, Haytowitz DB, Hubbard VS, Law D, Myrdal Miller A, Minor B, Percival SS, Riscuta G, Schneeman B, Thornsbury S, Toner CD, Woteki CE, Wu D. Mushrooms and Health Summit proceedings. J Nutr., 144(7) (2014) 1128S-1136S.
  • [13] Simmons EG., The International Mycological Association: its history in brief with summaries of its International Mycological Congresses and diverse international relationships, IMA Fungus., 1(1) (2010) 18-100.
  • [14] Asiegbu FO., Abu S., Stenlid J., Johansson M., Sequence polymorphism and molecular characterization of laccase genes of the conifer pathogen Heterobasidion annosum, Mycol Res., 108(Pt 2) (2004) 136-48.
  • [15] Haars A., Chet, I., Hüttermann A., Effect of phenolic com-pounds and tannin on growth and laccase activity of Fomes annosus, For. Pathol., 11(1–2) (1981) 67–76.
  • [16] Daniel G., Asiegbu F., Johansson M., The saprotrophic wood-degrading abilities of Heterobasidium annosum intersterility groups P and S, Mycol. Res., 102(8) (1998) 991-997.
  • [17] Doğmuş Lehtijarvi H., Lehtijarvi A., Oskay F., Aday A., Karadeniz M., Incidence of Annosum Root and but Rot on Abies Bornmulleriana and Abies Cilicica, ACUJFF., 9 (2008 ) 111-120.
  • [18] Korhonen K., Capretti P., Karjalainen R., Stenlid J., Distribution of Heterobasidion annosum intersterility groups in Europe. In: Heterobasidion annosum: Biology, Ecology, Impact and Control (Woodward S., Stenlid J., Karjalainen R., Hütterman A., eds), CAB International., (1998) 93–105.
  • [19] Garbelotto M., Gonthier P., Biology, epidemiology, and control of Heterobasidion species worldwide, Annu. Rev. Phytopathol., 51(1) (2013) 39-59.
  • [20] Sadowska A., Zapora E., Sawicka D., Niemirowicz-Laskowska K., Surażyński A., Sułkowska-Ziaja K., Kała K., Stocki M., Wołkowycki M., Bakier S., Pawlik A., Jaszek M., Muszyńska B., Car H., Heterobasidion annosum Induces Apoptosis in DLD-1 Cells and Decreases Colon Cancer Growth in In Vivo Model, Int J Mol Sci., 21(10) (2020) 3447.
  • [21] Kladar NV., Gavarić NS., Božin BN., Ganoderma: insights into anticancer effects, Eur J Cancer Prev., 25(5) (2016) 462-71.
  • [22] Glamočlija J., Ćirić A., Nikolić M., Fernandes Â., Barros L., Calhelha RC., Ferreira IC., Soković M., van Griensven LJ., Chemical characterization and biological activity of Chaga (Inonotus obliquus), a medicinal "mushroom", J Ethnopharmacol., 162 (2015) 323-32.
  • [23] Varmazyari A., Taghizadehghalehjoughi A., Sevim C., Baris O., Eser G., Yildirim S., Hacimuftuoglu A., Buha A., Wallace DR., Tsatsakis A., Aschner M., Mezhuev Y., Cadmium sulfide-induced toxicity in the cortex and cerebellum: In vitro and in vivo studies, Toxicol Rep., 7 (2020) 637-648.
  • [24] Bray F., Ferlay J., Soerjomataram I., Siegel RL., Torre LA., Jemal A., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin., 68(6) (2018) 394-424.
  • [25] Sadowska A., Sawicka D., Godlewska K., Guzińska-Ustymowicz K., Zapora E., Sokołowska E., Car H., Beneficial Proapoptotic Effect of Heterobasidion Annosum Extract in Colorectal Cancer Xenograft Mouse Model, Molecules., 28(3) (2023) 1352.
  • [26] Torres DM., Tooley KL., Butler RN., Smith CL., Geier MS., Howarth GS., Lyprinol only partially improves indicators of small intestinal integrity in a rat model of 5-fluorouracil-induced mucositis, Cancer Biol Ther., 7(2) (2008) 295-302.
  • [27] Bunz F., Hwang PM., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler KW., Vogelstein B., Disruption of p53 in human cancer cells alters the responses to therapeutic agents, J Clin Invest., 104(3) (1999) 263-9.
  • [28] Jakopovic, Boris, Nada Oršolić, and Sandra Kraljević Pavelić. "Antitumor, immunomodulatory and antiangiogenic efficacy of medicinal mushroom extract mixtures in advanced colorectal cancer animal model." Molecules 25.21 (2020): 5005.
  • [29] Dalman, K., Olson, A., Stenlid, J., 2010. Evolutionary history of the conifer root rot fungus Heterobasidion annosum sensu lato. Mol. Ecol. 19 (2010): 4979–4993.
  • [30] Linzer, R.E., Otrosina, W.J., Gonthier, P., Bruhn, J., Laflamme, G., Bussieres, G., Garbelotto, M.,. Inferences on the phylogeography of the fungal pathogen Heterobasidion annosum, including evidence of the interspecific horizontal genetic transfer and of human-mediated, long-range dispersal. Mol. Phylogenet. Evol. 46 (2008): 844–862.
  • [31] Hoque, E., Growth inhibitors produced by the in vitro culture of Heterobasidion annosum. Forest Pathol. 14 (1984): 43–51.
  • [32] Hirotani, M., O´ Reilly, J., Donnelly, D.M.X., Fomannoxin – toxic metabolites of Fomes annosus. Tetrahedron Lett. 18 (1977): 651–652.
  • [33] David Hansson, Sileshi Wubshet, Åke Olson, Magnus Karlsson, Dan Staerk, Anders Broberg, Secondary metabolite comparison of the species within the Heterobasidion annosum s.l. complex, Phytochemistry, 108 (2014): 243-251.
There are 33 citations in total.

Details

Primary Language English
Subjects Basic Pharmacology
Journal Section Natural Sciences
Authors

Çiğdem Sevim 0000-0002-0575-3090

Sabri Ünal 0000-0002-3026-0597

Temel Kan Bakır 0000-0002-7447-1468

Mertcan Karadeniz 0000-0002-3627-9424

Ali Taghizadeh Tgzd

Publication Date March 28, 2024
Submission Date September 8, 2023
Acceptance Date February 27, 2024
Published in Issue Year 2024Volume: 45 Issue: 1

Cite

APA Sevim, Ç., Ünal, S., Bakır, T. K., Karadeniz, M., et al. (2024). Cytotoxicity Analysis of the Effects of Heterobasidion Annosum Mycelia and Cisplatin on Colon Adenocarcinoma (CACO-2) Cell Line. Cumhuriyet Science Journal, 45(1), 105-110. https://doi.org/10.17776/csj.1357215
 Download Cover Image